Markus R. John - Concepedia

Author

Markus R. John

Novartis (Switzerland)

Also Known As

John McCabe, John, Markus, M R John, M. JOHN, M. John, M. R. John, M.R John, M.R. John, M.R. John⁎, Markus John

Publications

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Harvard University Massachusetts General Hospital Paracelsus Medical University Novartis Institutes for BioMedical Research

About

Markus R. John is an author at Novartis (Switzerland) specializing in medicine, endocrinology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	16	1.3K
2	Health Sciences	4	4	349
3	Natural Sciences	2	2	81
4	Engineering	1	1	18
5	Language Studies	1	1	18

Markus R. John

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Development of a Novel Immunoradiometric Assay Exclusively for Biologically Active Whole Parathyroid Hormone 1–84: Implications for Improvement of Accurate Assessment of Parathyroid Function Ping Gao, Stephen Scheibel, P D'Amour, Journal of Bone and Mineral Research	2001	377
A Novel Immunoradiometric Assay Detects Full-Length Human PTH but not Amino-Terminally Truncated Fragments: Implications for PTH Measurements in Renal Failure Markus R. John, William G. Goodman, Ping Gao, The Journal of Clinical Endocrinology & Metabolism Renal PathologyImmunologyPathologyFull-length Human PthPth Measurements	1999	287
Human PTH-(7-84) Inhibits Bone Resorption<i>in Vitro</i>Via Actions Independent of the Type 1 PTH/PTHrP Receptor Markus R. John, Harald Jüppner, F. Richard Bringhurst Endocrinology Linear SequenceParathyroid DiseaseParathyroid GlandOsteoporosisType 1	2002	181
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy Sarah Glover, Richard Eastell, Eugène McCloskey, Bone Bone DiseaseBiochemical MarkersBone ImagingRobust ResponseMedicine	2009	174
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial Gerd R Burmester, Frank Buttgereit, Corrado Bernasconi, The Lancet Rheumatoid DisorderRheumatologyLow Disease ActivityAutoimmune DiseaseRheumatic Diseases	2020	121
Quantitative MRI measures of cartilage predict knee replacement: a case–control study from the Osteoarthritis Initiative F. Eckstein, C. Kent Kwoh, Robert M. Boudreau, Annals of the Rheumatic Diseases	2012	119
Can Structural Joint Damage Measured with MR Imaging Be Used to Predict Knee Replacement in the Following Year? Frank W. Roemer, C. Kent Kwoh, Michael J. Hannon, Radiology	2014	97
Direct comparison of fixed flexion, radiography and MRI in knee osteoarthritis: responsiveness data from the Osteoarthritis Initiative W. Wirth, J. Duryea, M.-P. Hellio Le Graverand, Osteoarthritis and Cartilage Medical ImagingMusculoskeletal ImagingOsteoarthritis InitiativeChronic Musculoskeletal ConditionResponsiveness Data	2012	78
Greater rates of cartilage loss in painful knees than in pain‐free knees after adjustment for radiographic disease stage: Data from the Osteoarthritis Initiative F. Eckstein, Sebastian Cotofana, W. Wirth, Arthritis & Rheumatism	2011	65
Trajectory of cartilage loss within 4 years of knee replacement – a nested case–control study from the Osteoarthritis Initiative F. Eckstein, Robert M. Boudreau, Z. Wang, Osteoarthritis and Cartilage Osteoarthritis InitiativeCartilage LossChronic Musculoskeletal ConditionCartilage DegenerationOsteoarthritis	2014	50

Page 1